First Header Logo Second Header Logo

Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type.

Moore DC, Soni AC, Hu B, Smith ET, Levine J, Moyo TK, Jacobs R, Ghosh N, Park SI. Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B-cell lymphoma, leg type. Br J Haematol. 2022 Feb; 196(4):e30-e33.

View in: PubMed